<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238199</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000445077</org_study_id>
    <secondary_id>OHSU-GIM-02007-L</secondary_id>
    <secondary_id>OHSU-1104</secondary_id>
    <nct_id>NCT00238199</nct_id>
  </id_info>
  <brief_title>Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>Phase II Study of Calcitriol-Enhanced Docetaxel in Patients With Previously Untreated Metastatic or Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Calcitriol may cause pancreatic cancer cells to look more like normal cells, and&#xD;
      to grow and spread more slowly. Drugs used in chemotherapy, such as docetaxel, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Calcitriol may also help docetaxel work better by making the tumor cells&#xD;
      more sensitive to the drug. Giving calcitriol together with docetaxel may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving calcitriol together with docetaxel&#xD;
      works in treating patients with metastatic or locally advanced pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the time to progression in patients with metastatic or locally advanced&#xD;
           pancreatic cancer treated with calcitriol and docetaxel.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the median and one-year survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the overall response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the change in pancreatic cancer-induced pain in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: Patients receive oral calcitriol on days 1, 8, and 15 and docetaxel IV over 15-30&#xD;
      minutes on days 2, 9, and 16. Courses repeat every 4 weeks in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median and one-year survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pancreatic cancer-induced pain</measure>
  </secondary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcitriol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of pancreatic cancer&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  White blood cell (WBC) &gt; 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase (AP) &lt; 5.0 times ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) &lt; 2.5 times ULN&#xD;
             (if AP &lt; 2.5 times ULN) OR&#xD;
&#xD;
          -  ALT and AST &lt; 1.5 times ULN (if AP &gt; 2.5 times ULN and &lt; 5.0 times ULN)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.3 mg/dL&#xD;
&#xD;
          -  Calcium &lt; 10.5 mg/dL&#xD;
&#xD;
          -  Phosphate &lt; 4.7 mg/dL&#xD;
&#xD;
          -  No kidney stones within the past 5 years&#xD;
&#xD;
          -  No history of hypercalcemia&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No uncontrolled heart failure with a known ejection fraction &lt; 30%&#xD;
&#xD;
          -  No other significant heart disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No hypersensitivity to docetaxel or other drugs formulated with polysorbate 80&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No comorbid condition that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  No prior chemoradiotherapy for locally advanced disease&#xD;
&#xD;
          -  No prior adjuvant docetaxel&#xD;
&#xD;
               -  Other prior adjuvant chemotherapy allowed&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 30 days since prior investigational surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 7 days since prior and no concurrent digoxin or thiazide diuretic therapy&#xD;
&#xD;
          -  More than 30 days since prior investigational therapy&#xD;
&#xD;
          -  No concurrent magnesium-containing antacids, bile resin-binding drugs, or calcium&#xD;
             supplements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles D. Blanke, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <last_update_submitted>April 22, 2015</last_update_submitted>
  <last_update_submitted_qc>April 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2015</last_update_posted>
  <responsible_party>
    <name_title>Charles Blanke</name_title>
    <organization>Oregon Health and Science University Knight Cancer Institute</organization>
  </responsible_party>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

